Compare DexCom, Inc. (DXCM) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MasTec Inc — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while MasTec Inc trades at $212.65 (market cap $17.40B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and MasTec Inc for 23 Days on average.
| DXCM | MTZ | |
|---|---|---|
Market Cap | $31.86B | $17.40B |
Volume | 3,607,070 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $92.34 | $437.51 |
52-Week Low | $54.84 | $190.08 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $31.32B | $20.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
MasTec (MTZ) trades at $216.66, down 3.0% on the day, amid bearish technical signals despite strong analyst support. The stock shows mixed earnings performance with recent Q2 2026 EPS missing expectations, but maintains robust revenue growth projections and a record $21.4B backlog. Current valuation metrics include a P/E of 34.5 and P/S of 1.06, while profitability metrics show a 3.07% net income margin and 15.39% ROE.
The investment outlook remains positive based on strong analyst consensus (88.9% buy ratings) and a $408.58 price target, representing significant upside potential. Key opportunities include infrastructure investment cycles and AI-driven data center demand, while risks include premium valuation, weak cash flow trends, and communications segment softness. The stock's current price near support levels offers potential entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
